CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 30 target
Drug / intervention
Markerless Image Guidancedevice
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less)
  • ✓Undergoing external beam radiotherapy
  • ✓Tumor diameter 1-5 cm in any dimension
  • ✓Distance between tumor centroid and top of diaphragm ≤10 cm
Key exclusion· 8
  • ✕Low respiratory performance as evaluated by physicians
  • ✕Previous high-dose thoracic radiotherapy
  • ✕Less than one fiducial marker implanted in lung
  • ✕Fiducial markers >9 cm from tumor centroid

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04086082
NCT04086082N/ARecruitingOn Track
Long Recruiting
CompareCT.gov

MAGIK: Using Implanted Markers to Determine the Feasibility of Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging: A Phase I Interventional Study of Lung Cancer Radiotherapy

University of Sydney·interventional·Posted Sep 11, 2019·Updated May 20, 2026

In Brief

A clinical study evaluating Markerless Image Guidance for Lung Cancer. Currently recruiting, targeting 30 participants across 1 site.

Detailed Summary

This trial will investigate the feasibility of the Markerless Tumour Tracking technology.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesAustralia
Collaborators--

Timeline

N/ARecruiting
2020202120222023202420252026202720282029
First PostedSep 11, 2019
Enrollment StartMay 24, 2023
Primary CompletionDec 1, 2028
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 6.8 years agoPrimary completion in 2.4 years

Interventions

Markerless Image Guidancedevice

Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging